Revenue
2023
2024
2025
NRX Pharmaceuticals, Inc. (NRXP)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $0 | $0 | — | — | — | — | — |
| Research & development | $3.8M | $6.2M | $13.4M | $17.0M | $20.3M | $10.6M | — | — |
| Operating expenses | — | $18.5M | $27.8M | $44.3M | $115.8M | $51.4M | $713,187 | $1.0M |
| Operating income | −$16.2M | −$18.5M | −$27.8M | −$44.3M | −$115.8M | −$51.4M | −$713,187 | −$1.0M |
| EBITDAderived | −$16.2M | −$18.5M | — | — | — | — | — | — |
| Net income | −$28.6M | −$25.1M | −$30.1M | −$39.8M | −$93.1M | −$51.8M | $408,427 | $66,101 |
| Basic EPSper diluted share | -$1.34 | -$2.36 | -$3.98 | -$0.60 | -$1.98 | -$1.51 | -$0.11 | -$0.29 |
| Diluted EPSper diluted share | — | — | — | -$0.60 | -$1.98 | -$1.51 | -$0.11 | -$0.29 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 17, 2024Form 4 | Javitt Jonathan CChairman and Chief Scientist | BuyCommon Stock | 40.0K | $1.17 | $46.8K | 84.6K |